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Abstract.The glucokinase (GCK) gene was one of the
first candidate genes to be identified as a human
“diabetes gene”. Subsequently, important advances
weremade in understanding the impact ofGCK in the
regulation of glucose metabolism. Structure elucida-
tion by crystallography provided insight into the
kinetic properties of GCK. Protein interaction part-
ners of GCK were discovered. Gene expression
studies revealed new facets of the tissue distribution
of GCK, including in the brain, and its regulation by
insulin in the liver.Metabolic control analysis coupled
to gene overexpression and knockout experiments
highlighted the unique impact of GCK as a regulator
of glucose metabolism. Human GCK mutants were
studied biochemically to understand disease mecha-
nisms. Drug development programs identified small
molecule activators of GCK as potential antidiabetics.
These advances are summarized here, with the aim of
offering an integrated view of the role of GCK in the
molecular physiology andmedicine of glucose homeo-
stasis.
Keywords. Glucokinase, diabetes, glucose metabolism, insulin, hexokinase, islet of Langerhans, hepatocyte,
MODY.
Introduction
This review focuses on the enzyme known as mamma-
lian glucokinase. Somewhat ironically, this enzyme is
actually not a glucokinase in the strict sense, denoting
a glucose phosphorylating enzyme with stringent
substrate specificity for glucose, such as exists in
lower organisms. Mammalian glucokinase is able to
phosphorylate hexoses like mannose or fructose in
addition to glucose, a property sharedwith three other
hexokinases present at various levels and in various
combinations in human, rat, and mouse tissues [1].
The four mammalian isoenzymes display extensive
sequence identities, leaving no doubt about a close
phylogenetic relationship [2], and arguing for the
terminology hexokinases I– IV (or A–D), in which
hexokinase IV (or D) designates mammalian gluco-
kinase. In spite of these considerations, the term
glucokinase has become entrenched in tradition,
probably because it conveys a sense of the very unique
role of this enzyme in the regulation of glucose
homeostasis. This tradition is followed in the current
article, with the understanding that glucokinase
(GCK) stands for hexokinase IV (or D). Whether
the name should be reconsidered in the future is an
open question, because a gene encoding a functional
ADP-dependent glucokinase reminiscent of primitive
organisms was recently identified in the mouse and
human genomes [3]. The level of activity and physio-
logical role of this enzyme in mammalian tissues are
currently unknown.
Glucokinase was identified as an enzyme of rat liver in
1962. In 1992, two studies using the candidate gene
approach reported a genetic linkage between a form
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of maturity onset diabetes of the young, named
MODY 2, and the GCK gene [4, 5]. This discovery
came as the culmination of three decades of research
in biochemistry, physiology and molecular biology,
which collectively demonstrated the preferential ex-
pression of GCK in hepatocytes and b-cells of the
pancreas, and suggested a key role in glucose metab-
olism. These investigations, which had conferred to
GCK the rank of prime candidate as a “diabetes
gene”, were the subject of two reviews published in
1993 [6, 7].
In recent years our perception of the pivotal role of
GCK in the regulation of glucose metabolism has
been reinforced by important results in a variety of
experimental areas. Structural investigations by X-
ray crystallography shed new light on the very
special enzyme kinetics of GCK. Gene expression
studies revealed novel facets of the tissue distribu-
tion of GCK, notably in brain, and of the insulin
regulation of expression in the liver. Genetic
manipulations in cells and mice led to major
advances in our understanding of the glucose sensor
function of GCK at the cellular level and its impact
on whole body glucose homeostasis. This article was
written to assemble knowledge from very diverse
lines of investigation, with the aim of offering an
integrated view of the unique place of GCK in
physiology and medicine.
Three-dimensional structure of GCK: cooperative
glucose kinetics explained
Glucose taken up by mammalian cells has to be
converted into glucose 6-phosphate as a prelude to
further utilization for glycolysis, the pentose phos-
phate pathway or glycogen synthesis. Although some
contribution to overall glucose phosphorylation by the
recently identified ADP-dependent glucokinase [3]
cannot be ruled out, the bulk of glucose phosphor-
ylation occurs at the expense of ATP in the generic
reaction catalyzed by the hexokinases: hexose+ATP
! hexose 6-phosphate +ADP [8].
Among the hexokinases, GCK displays unique en-
zyme kinetics in two respects. First, GCK has an
affinity for glucose (S0.5 ﬃ 6 mM) more than 20 times
lower than that of the next ranking hexokinase,
hexokinase II. Second, the rate of the GCK reaction
displays a sigmoid rather than hyperbolic dependence
on glucose concentration [1]. These two kinetic
properties, low affinity and cooperativity with respect
to glucose, allow GCK to operate as an ultrasensitive
physiological glucose sensor in cells endowed with
non-limiting glucose transport activity at the plasma
membrane (see below).
The cooperativity of GCK with glucose cannot be
explained by the classical mechanisms of allostery for
multisubunit proteins, because GCK is catalytically
active in the monomeric state [9]. Moreover, GCK
harbours a single glucose binding site (the active site)
[10], excluding the possibility of multisite allostery in
which two molecules of glucose would bind simulta-
neously to the enzyme. Deviation from hyperbolic
kinetics is sometimes noted for monomeric enzymes
in case of random addition of substrates, but this is not
the case for theGCK catalytic cycle, which involves an
ordered addition of substrates in which glucose binds
first and ATP second [11]. A mechanism of positive
cooperativity applicable to monomeric enzymes,
named the mnemonic model, was proposed for GCK
on the basis of early enzymological investigations [12].
Predictions from the mnemonic model were con-
firmed by recent studies using pre-steady-state meas-
urements of the intrinsic fluorescence of GCK during
binding of glucose and other ligands [13, 14]. The
mnemonic mechanism of cooperativity includes the
following features: i) equilibrium between two con-
formational states of GCK with vastly different
glucose affinities; ii) large predominance of the low
affinity conformation in the absence of glucose; iii)
slow interconversion between the conformational
states for glucose-free GCK; iv) conversion from the
low affinity to the high affinity conformational state
strongly accelerated upon glucose binding to GCK; v)
only the high affinity form of the enzyme is catalyti-
cally competent, and the rate of the catalytic step(s) is
very fast compared to the conformational transition
rate.
Explicit support for the model came recently from
structural data on human GCK obtained by Kamata
and colleagues, who solved the structure of GCK by
X-ray crystallography [15]. Crystals were obtained
fromGCKwith short truncations at the NH2-terminal
end (11 or 15 amino acids) under two distinct
crystallization conditions: in the presence of glucose
plus a small-molecule activator of GCK (see below),
or in the absence of any ligand. The overall structure
of the protein was comprised of a large and a small
globular domain connected by a hinge made up of
three flexible loops. With glucose and the activator
present, the space between the two domains assumed
the shape of a narrow, deep cleft containing the
glucose binding pocket. The binding site for the
activator was also localized in the hinge region, at a
distance from the glucose binding pocket. The struc-
ture was very similar to that of the C-terminal half of
hexokinase I crystallized in the presence of glucose,
called the closed form of hexokinase, and was there-
fore designated the “closed” form of GCK. By
contrast, GCK crystals formed without ligands dis-
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played the so-called “super-open” conformation. In
this configuration, the cleft space between the two
domains of GCK was much broader, as the result of
two conformational changes compared to the closed
form: tilt and rotation of the small domain with
respect to the large domain, and extensive rearrange-
ment of the secondary structural elements of the small
domain itself [15].
The two X-ray structures of GCK could readily be
fitted into the mnemonic model of enzyme mecha-
nism. The super-open conformation represents the
low glucose affinity, catalytically inactive form of
enzyme. The closed conformation corresponds to the
high affinity form of GCK with glucose and ATP
bound at the active site during catalysis. An additional
conformation of GCK, intermediary between the
super-open and the closed states, was postulated for
the high affinity form of the enzyme free of substrates
or products. This putative conformation was desig-
nated the “open” form. The crystal structure of GCK
in the open form remains to be established. However,
X-ray diffraction studies of crystals of the C-terminal
half of hexokinase I formed in the absence of glucose
can serve as a model for the open form. Compared to
the closed form, the open form displayed a wider
interdomain cleft due to slight twist of the small
domain relative to the large domain, without change
in the internal topology of the small domain core [16].
The transition between open and closed conforma-
tions would be very fast and easily reversible, in
contrast to the more complex molecular reorganiza-
tion involved in the slow transition from the super-
open to the open conformations. Indeed, the predic-
tion of an intermediary open state of GCK was borne
out in a recent study using targeted molecular
dynamics simulation to dissect the transition from
the closed to the super-open configurations of GCK
[17].
Regulation of glucokinase activity by protein-protein
interaction
Interaction with hepatic glucokinase regulatory pro-
tein. The best understood mechanism of rapid regu-
lation of GCK activity relies on protein-protein
interaction between GCK and a partner termed
GCK regulatory protein (GCKR). The association
between the two proteins is ligand-dependent and
inhibitory to GCK activity. Ligands for GCKR are
fructose-6-phosphate and fructose-1-phosphate,
which are mutual competitors. Binding of fructose 6-
phosphate to GCKR favors the GCKR-GCK inter-
action with a negative effect on enzyme activity, while
binding of fructose-1-phosphate weakens the GCKR-
GCK interaction and releases active GCK. Intra-
hepatic fructose-1-phosphate rises postprandially
after intestinal absorption of fructose and its con-
version to fructose-1-phosphate by liver fructokinase.
Conversely, inhibition of GCK by fructose-6-phos-
phate liganded to GCKRwould provide a mechanism
for indirect negative feedback, since fructose 6-
phosphate is in equilbrium with glucose 6-phosphate
(the product of the GCK reaction) through the
phosphohexose isomerase step of glycolysis [18].
The conformational state of GCK preferred for
binding to GCKR is the super-open form. This was
suggested by experiments in a cell-free assay with
purified proteins, in which the association of GCK
with GCKR was estimated by co-immunoprecipita-
tion. The amount of GCK associated with GCKRwas
reduced under conditions favoring the closed con-
formational state of GCK, that is during incubation at
elevated glucose concentrations in the presence of
ATP, or in the presence of glucose together with a
small molecule activator of GCK. This suggested that
the interface for binding toGCKRwould be disrupted
by the conformational transition from the super-open
to the closed forms of GCK [19].
The reversible association of GCK with GCKR does
more than simply regulate the catalytic activity of
GCK, it also appears to underlie the intracellular
trafficking ofGCKbetween cytoplasm and nucleus. In
transfected rat hepatocytes, GCK tagged with green
fluorescent protein was localized in the nucleus at low
glucose and was released to the cytoplasm at high
glucose, but GCK mutants with reduced affinity for
GCKRwere predominantly cytoplasmic at low as well
as high glucose [20]. In cell lines devoid of GCK and
GCKR, such as COS-1, HeLa and HEK293T cells,
forced expression of GCK alone resulted in cytoplas-
mic localization, whereas co-expression with GCKR
resulted in nuclear accumulation of both proteins [20–
22]. In a rat islet b-cell line with no endogenous
GCKR, doxycycline-inducible expression of GCKR
resulted in nuclear accumulation of GCKR together
with translocation of endogenous GCK from an
extranuclear localization to the nuclei [22].
A model (Fig. 1) to account for these results proposes
that GCKR in the free state would shuttle between
nucleus and cytoplasm. Under low glucose conditions,
the assembly of GCKR-GCK complex would result in
nuclear import and trapping of both proteins by
molecular mechanisms not yet completely elucidated.
Masking of a nuclear export sequence (NES) between
amino acids 300 and 310 of GCK sequence would be
part of this mechanism [21]. In metabolic states
accompanied by high glucose or fructose-1-phosphate
concentrations, and sufficient ATP levels [23], the
GCK-GCKR complex would dissociate and the NES
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of GCK would become functional, allowing for the
rapid export of GCK from nuclei. In the isolated
perfused liver system and in primary cultures of rat
hepatocytes, GCK and GCKR were indeed mainly
localized to the nuclei at glucose concentrations
around 5 mM. Higher glucose levels or fructose
addition to the medium caused a rapid translocation
of GCK to a predominant cytoplasmic localization
[24, 25]. This was accompanied to a lesser degree by
redistribution of GCKR to the cytoplasm [26, 27]. As
predicted by this model, mice with homozygous
inactivation of the GCKR gene had an extranuclear
localization of hepatic GCK under all metabolic
conditions [28, 29]. Interestingly, the steady state
amount ofGCK in the liver was reduced about 50% in
the GCKR knock-out animals, suggesting the possi-
bility that the interaction with GCKR might stabilize
GCK against degradation.
Recently, a minor fraction of GCK and GCKR in
hepatocytes was reported to be associated with the
mitochondrial fraction, raising the suggestion of
distinct pools of cytoplasmic GCK with specialized
metabolic functions [30]. However, this notion should
be considered with caution, because other authors
failed to detect GCK activity or immunoreactivity in
isolated mouse liver mitochondria [31].
Interaction with other proteins. The impact of the
GCKR model led several investigators to search for
newprotein partners thatmight affectGCKactivity or
localization, notably in the islet b-cells in which
GCKR is essentially absent. A list of GCK interacting
proteins with their major properties is given in
Table 1. For virtually all of these proteins other than
GCKR, additional investigations are necessary for
definitive proof that the proposed interaction with
GCK has an impact on GCK activity and/or cell
function.
The bifunctional enzyme 6-phosphofructo-2-kinase/
fructose-2,6-bisphosphatase (PFKFB) is responsible
for the regulated formation and degradation of
fructose 2,6-bisphosphate, a key allosteric activator
of the enzyme 6-phosphofructo-1-kinase, and thereby
of glycolysis. An interaction of the fructose-2,6-bi-
sphosphatase domain of PFKBP with GCK was
demonstrated in a yeast two-hybrid system [34].
Overexpression of PFKBP in insulinoma b-cells
resulted in increased GCK specific activity without
increase in the cellular content of GCK protein [35,
36]. Although provocative, the published studies did
not directly demonstrate an association of GCK with
PFKFB in mammalian cells, nor did they provide
insight into a possible mechanism for the apparent
increase in GCK activity in cells co-expressing
PFKBP. These issues should be further investigated
before a conclusive model of GCK regulation by
association with PFKBP becomes widely accepted.
A model in which neuronal nitric oxide synthase
(NOS)would serve to anchorGCK to the periphery of
insulin secretory granules in the basal state in bTC3
insulinoma cells was proposed by Rizzo and Piston
[37]. Autocrine activation of NOS by insulin during
Figure 1. Regulation of GCK activity and subcellular localization by interaction with GCKR. The scheme depicts hepatocytes after an
overnight fast (postabsorptive) and during the ingestive phase after a carbohydrate containing meal (postprandial). The nuclear
compartment (circle) communicates with the cytoplasmic space by nuclear pores. The blue and cyan ovals represent the large and small
lobes of GCK respectively. After carbohydrate ingestion, the glucose concentration in plasma and hepatocytes rises, as does the
concentration of fructose-1-phosphate.As a result, theGCKR(red)-GCK interaction is loosened, allowingGCK tobind glucose, adopt the
closed (catalytically active) conformation and exit from the nucleus to generate glucose-6-phosphate for glycogen synthesis and glycolysis.
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glucose stimulated secretion would stimulate the
nitrosylation of GCK on a specific cysteine residue,
and its release from the granules to the cytosol. The
general validity of this model remains uncertain,
however, because glucose-induced translocation of
GCK from the secretory granules to the cytosol was
not confirmed in MIN6 insulinoma cells [38].
Human GCK was recently found to be polyubiquiti-
nated at multiple Lys residues in a cell-free system.
Additionally, a sequence motif compatible with an
ubiquitin interacting consensus was identified in the
C-terminal a-helix of humanGCK. This motif was the
target for non-covalent binding of free pentaubiquitin
chains in a cell-free system. Ubiquitin chains added to
a GCK enzyme assay mixture resulted in an increased
Kcat [39]. The occurrence and physiological implica-
tion of this interaction in living cells were not
investigated.
Multiprotein assembly at the outer mitochondrial
membrane. In investigations of the function of the
BH3-only proapoptotic protein BAD, Danial and
colleagues described a large multimolecular assembly
comprising BAD, GCK and other proteins in a highly
purified mitochondrial fraction from the mouse liver
[40]. Analysis of the supramolecular complex using
immunochemistry and LC-tandem MS peptide anal-
ysis revealed that the complex contained GCK and
BAD, as well as the Wiskott–Aldrich family member
WAVE, the catalytic subunits of protein phospatase 1
(PP1) and of protein kinase A (PKA). The essential
protein in nucleating the complex appeared to be
BAD, since the complex was absent in BAD knock-
out (BAD-/-) mice. The oxidative metabolism of
glucose was reduced in hepatocytes from BAD-/-
mice, suggesting a function of the complex in meta-
bolic regulation. However, caution is warranted,
because GCK associated with mitochondria was a
very small fraction of the total [40], if present at all
[31]. Complicating the matter further, the role and
regulation of the protein kinase and phosphatase
associated with the complex remain elusive.
The relevance of the Danial complex was recently
extended to the b-cells of the islets of Langerhans [41].
Perifused islets from BAD-/- mice displayed glucose
unresponsive insulin secretion. Total assayable GCK
activity in islet homogenates from BAD-/- mice was
reduced to less than 30% of the wild-type level.
Glucose-sensitive insulin release was restored after
treatment of islets from BAD-/- animals with cell-
permeable synthetic peptides corresponding in se-
quence to aBH3a-helix ofBAD. Peptides harboring a
phosphomimetic Ser 155 toAspmutation were active,
while a peptide with an Ala mutation was ineffective.
Peptides active in the insulin secretion assay also
induced strong increases in GCK activity when added
to INS-1 insulinoma cells in culture. Furthermore,
photoactivatable BAD peptides were shown to cross-
link with GCK in homogenates of INS-1 cells. It is
worth pointing out that a much larger fraction of
cellular GCK appeared to be under BAD control in
the islets than in the liver. Whether most or all of the
GCK interacting with BAD resided at the outer
mitochondrial membrane in islet cells was not exper-
imentally demonstrated.
Table 1. Protein interaction partners of glucokinase.
Name Method of identification Biochemical
effects
Cellular effects References
glucokinase regulatory
protein (GCKR)
protein purification from liver extract inhibits GCK
activity
regulates GCK activity and
localization in hepatocytes
reviewed
in [18]
glucokinase-associated-
phosphatase
yeast two-hybrid system increases GCK
activty
unknown [32]
propionyl-CoA
carboxylase b-subunit
yeast two-hybrid system increases GCK
affinity and
activity
unknown [33]
6-phosphofructo-2-
kinase/fructose-2,6-
bisphosphatase
screening of random peptide display phage
library for binding to GCK
no effect in GCK
activity assay
overexpression in insulinoma
cells increases GCK activity
[34–36]
neuronal nitric oxide
synthase
co-immunoprecipitation nitrosylates
GCK
anchors GCK to the periphery
of insulin secretory granules
[37]
pentaubiquitin identification of ubiquitin interacting motif
in GCK
increases GCK
affinity and
activity
unknown [39]
bad peptide analysis of multiprotein complex in
liver mitochondrial fraction,
immunochemistry
increases GCK
activity
regulates GCK activity and
localization in hepatocytes and
b-cells
[40, 41]
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Regulation of glucokinase gene expression
Tissue-specific promoters. A defining feature of the
GCK gene in mammalian species is the presence of
two alternative promoters. The promoters are sepa-
rated by approximately 30 kbp of genomic DNA and
responsible for transcription initiation in a mutually
exclusive manner in distinct tissues. The upstream
promoter and adjacent leader exon drive the synthesis
of GCK mRNA in non-hepatic tissues, that is islet
cells, enteroendocrine cells, specialized glucose-sensi-
tive neurons in the central nervous system (CNS), and
additional scattered cells in various tissues [42]. This
promoter is denominated the neuroendocrine pro-
moter. By contrast, the downstream so-called liver
promoter and its associated leader exon serve for
transcription initiation in hepatocytes only. Each of
the leader exons specifies the 5 untranslated regions
of the mRNAs as well as the first 15 codons for the
GCK protein sequences, which therefore differ at
their NH2-terminal ends in liver and other tissues.
During splicing of the primary transcripts, the donor
splice sites at the end of the neuroendocrine or liver
leader exons are ligated to the acceptor site of a
common exon 2 and further splicing incorporates
common exons 3–10 in the two types of mRNAs.
Thus, the GCK enzymes in neuroendocrine cells and
hepatocytes have a common amino acid sequence
over most of their length. There is currently no known
functional difference in the GCK enzymes arising
from the short distinct leader sequences.
Alternative promoters allow for the control of tran-
scription initiation by distinct sets of cis-acting regu-
latory elements in different tissues. In early experi-
ments,Magnuson and colleagues showed that a 294 bp
rat DNA fragment of the neuroendocrine promoter
activated the expression of luciferase in insulinoma
cells, but not 3T3-preadipocytes [43]. In transgenic
mice, the sameDNA fragment drove the expression of
a human growth hormone reporter gene in pancreatic
islet cells, intestinal cells and brain cells [42]. Two
major functional cis-acting elements were delineated
in this promoter fragment [43]. One element bound
proteins which did not match known transcription
factors [44], whereas the other element was identified
as a binding site for Beta2/NeuroD, a basic helix-loop-
helix zipper (bHLHz) transcriptional activator im-
portant in the ontogeny of the endocrine pancreas
[45]. Another key transcription factor of early pan-
creas development, Pdx-1, was proposed to activate
the neuroendocrine GCK promoter [46], but this
notion was subsequently dispelled [47].
There are no published investigations using transgenic
mice to define the regulatory sequences responsible
for the hepatocyte-specific activity of the liver GCK
promoter. In transient transfection assays, a 200 bp
liver promoter fragment from the rat gene was
competent to stimulate the expression of a luciferase
reporter in primary hepatocytes andhepatoma culture
cells, but not in insulinoma cells [48, 49]. More
importantly, a 300 bp enhancer active only in primary
hepatocytes was mapped between nucleotides -1000
and -700with respect to the start of transcription of the
rat gene and at a similar position in the human gene.
This sequence exhibited 6 DNAse I protection foot-
prints, but the identity of the binding proteins was not
elucidated [48].
Transcriptional induction of gene expression by
insulin in liver. In the liver, expression of GCK is
strictly dependent on the presence of insulin. Thus,
GCKmRNA and protein disappear from the livers of
insulino-deficient rats and are restored after insulin
treatment [50]. In cultured rat hepatocytes, the effect
of insulin as inducer of GCK was shown to be
primarily at a transcriptional level, triggering a 15-
to 30-fold increase in GCKmRNA in three hours, and
taking place in glucose-free as well as glucose-
containing medium without any synergy by addition
of glucose [6]. Induction of GCK by insulin and
repression by glucagon were also documented in
hepatocytes isolated from the human liver [51].
Insulin induction ofGCK in hepatocytes was shown to
be suppressed by the inhibitors of phosphoinositide 3-
kinase (PI3-kinase) wortmannin and LY294002, im-
plying that activation of PI3-kinase following insulin
binding to its receptor was essential. Protein kinase B
(PKB, also called Akt) is a major protein kinase
activated as a result of PI3-kinase stimulation. To test
for a possible role of PKB in mediating GCK
induction, hepatocytes were transduced for expres-
sion of an estrogen receptor-PKB chimeric protein
that could be conditionally activated by tamoxifen.
The transduced hepatocytes reponded to the addition
of tamoxifen by a rise of GCKmRNA, mimicking the
effect of insulin [52]. In separate experiments, insulin
induction of GCKmRNAwas abrogated by inhibitors
of PKB activation [53, 54]. Additionally, GCKmRNA
and protein were induced in the livers of streptozo-
tocin diabetic mice following in vivo transduction of
adenoviruses encoding kinase active versions of
PFKFB, a maneuver that unexpectedly triggered the
activation of PKB [55]. A role of PKB in insulin
induction of GCK was questioned by Matsumoto and
colleagues [56], who observed that they could inhibit
insulin-mediated induction of GCK mRNA in hep-
atocytes by expressing a dominant negative NH2-
terminal fragment of insulin receptor substrate-1
(IRS-1), while PKB activation apparently remained
unaffected. An explanation for this negative result
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might be that GCK induction is mediated by a minor
pool of PKB functionally associated with IRS-1,
making a small contribution in assays of total cellular
PKB activity and therefore difficult to quantify.
The transcriptional regulators which respond to the
insulin activation of PKB (and perhaps of accessory
signaling cascades) and stimulate transcription at the
liver GCK promoter remain elusive. The sterol-
regulatory element binding protein SREBP1c, a
master regulator of lipogenic enzymes such as fatty
acid synthase (FAS) and acetyl-CoA carboxylase
(ACC), was proposed to be a mediator of insulin
induction of GCK. Briefly, SREBP1c itself was shown
to be induced at the transcriptional level by insulin in
hepatocytes [57, 58]. Overexpression of SREBP1c in
primaryhepatocyteswas accompanied by an elevation
of GCKmRNA and, conversely, a dominant negative
mutant of SREBP1c inhibited insulin-dependent in-
duction of GCK mRNA [59]. More recently, inves-
tigators identified a tandem DNA element around
position -200 in the rat liver GCK promoter, which
could bind bacterially expressed mature SREBP1c in
DNAse protection assay and electrophoretic mobility
shift assay (EMSA) [60]. However, in other inves-
tigations, inducible expression of mature SREBP1c in
hepatocytes failed to produce a significant increase of
GCK mRNA [61]. In SREBP1c ko mice, GCK
mRNA was induced normally during the fasting-
refeeding transition [62]. Moreover, liver transduc-
tion of adenovirus encoding active PKB (i.e. mimick-
ing insulin signaling) resulted in strong induction of
hepatic GCKmRNA in normal as well as SREBP1 ko
mice [63]. In our own experiments in insulin stimu-
lated hepatocytes, SREBP1c failed to bind to the liver
GCKpromoter, while its binding to the FAS promoter
was readily discerned by chromatin immunoprecipi-
tation [64]. Also, insulin produced amore than 10-fold
augmentation ofGCKmRNAamount in a time frame
in which there was strictly no increase in transcrip-
tionally mature SREBP1c protein. Vice-versa, activa-
tion of the nuclear receptor liver X receptor (LXR)
with a synthetic ligand produced a strong induction of
SREBP1c and its target gene FAS without any rise of
GCK mRNA [64]. Together, these results seem to
virtually rule out a determinant role of SREBP1c in
the rapid induction of liver GCK by insulin in rat
hepatocytes.
Binding sites for the transcriptional activators hep-
atocyte nuclear factor-4 (HNF-4) and hypoxia-indu-
cible factor-1a (HIF-1a) were identified within the
first 100 bp of the liver GCK promoter [65, 66]. Co-
expression of HNF-4 and HIF-1a with GCK reporter
plasmids in primary rat hepatocytes resulted in
additive transactivation of the GCK promoter,
which was further augmented by expression of the
co-activator p300. More importantly, co-transfection
of plasmids encoding constitutively active PI3K or
PKB stimulated GCK promoter activity, as long as an
intact binding site for HIF-1a was present in the
promoter DNA fragment. Together, these findings
suggested that co-operation between HNF-4, HIF-1a
and p300 at the liver GCK promoter might be
important for induction of the gene in response to
acute insulin signaling [66]. The proposal that HIF-1a
might be a mediator in insulin signaling is significant,
because hypoxia and insulin were previously shown to
synergize in inducing GCK gene expression in cul-
tured hepatocytes [67]. This type of synergy might in
part account for the enrichment of insulin inducible
enzymes such as GCK in the underoxygenated
perivenous region of the liver lobule, compared to
the periportal region [68]. Based on findings in
another system, insulin might hypothetically induce
HIF-1a target genes by relieving HIF-1a from co-
repression by a forkhead box class O (FOXO) factor,
through a mechanism involving PKB-mediated phos-
phorylation and functional inactivation of FOXO
[69]. However, arguing against this possibility, levels
of hepatic GCK mRNA in adult mice with liver
specific knockout of FOXO1 were similar to those of
control mice in both the fasted and fed states [70].
Hormone and nutrient regulation of glucokinase gene
expression in islets of Langerhans.Glucose refeeding
after a fast is an experimental paradigm often used to
study acute hyperinsulinemia in the intact animal.
Consistent with data in cultured hepatocytes, GCK
mRNA was virtually absent from the livers of fasted
rats and accumulated massively within hours of
feeding a glucose-enriched diet [71]. By contrast,
GCK mRNA and protein levels in islets of Langer-
hans were not significantly depressed in fasted rats
compared to freely fed animals and,more importantly,
were not acutely induced during the fasting-refeeding
transition [72]. Thus, constitutive expression of GCK
in the pancreatic islets contrasted with inducible GCK
gene expression in the liver.
In the MIN6 insulinoma cell line, GCK mRNA was
higher during culture at 30 mM than at 3 mM glucose
concentration, or following the addition of subnano-
molar concentrations of insulin to the medium [73].
However, luciferase reporter plasmids driven by the
neuroendocrineGCKpromoter were unaffected after
a rise in glucose or insulin concentrations [74],
suggesting that, in insulinoma cells, the major effects
of glucose or insulinmight be to stabilizeGCKmRNA
against degradation rather than stimulate transcrip-
tion from the neuroendocrine promoter. In rat INS-1
insulinoma cells, GCKmRNAand protein levels were
increased about 50% after 24 hours of culture in the
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presence of insulin-like growth factor-1 (IGF-1),
consistent with a modest transcriptional effect of
IGF-1. An inhibitory cis-acting DNA element target-
ed by FOXO1 was identified at position 500 in the
neuroendocrine promoter. Thus, FOXO1might act in
this system as a repressor, itself negatively regulated
by IGF-1 [75].
Metabolic role of hepatic glucokinase
Regulatory role of glucokinase at the hepatocellular
level. The liver is equipped with an insulin-independ-
ent facilitative glucose transport system (now known
to be mostly by GLUT2) with apparent affinity
constant of 17 mM and high transport rate, allowing
extremely rapid equilibration of the glucose concen-
tration across the hepatocyte plasma membrane [76].
Unlimiting glucose transport, and the unique glucose
affinity ofGCK (which is the predominant hexokinase
isoenzyme in the liver), ensure that fluctuations of the
plasma glucose concentration are rapidly translated
into changes in the rate of glucose phosphorylation
inside the hepatocyte. If, in turn, the GCK reaction
controls the substrate flux along the entire length of
the pathways from glucose to final products, the
overall metabolic rate in these pathways will be
regulated autonomously in response to changes in
the plasma glucose concentration.
In hepatocytes with adenovirus mediated overexpres-
sion of GCK, compared to hepatocytes transduced
with control vectors, rates of glycogen synthesis were
augmented in proportion to GCK activity [77, 78].
This effect was attributed to an increase in the cellular
content of glucose-6-phosphate, a product of theGCK
reaction and an allosteric activator of glycogen
synthase [79]. Overexpression of GCK also resulted
in proportionate stimulation of glycolysis and glucose
oxidation [80, 81]. As stated above, the fact that GCK
exerts dominant control on glycogen synthesis and
glycolysis has a crucial physiological implication: it
confers to hepatocytes the ability for cell autonomous
regulation of glucose metabolism in response to
fluctuations of the plasma glucose.
Regulatory role of liver glucokinase at the organismal
level. The impact of altering liver glucokinase activity
on whole body glucose homeostasis was illustrated in
transgenic mice with an extracopy of the GCK gene
locus. These animals had an approximately 50%
increase in hepatic GCK activity over the wild-type
level and a 25% reduction in plasma glucose in the
postabsorptive state, reflecting increased glucose
clearance. During an hyperglycemic clamp, overall
glucose utilization was similar in control and trans-
genic mice, in spite of plasma insulin levels that were
40% lower in the transgenics. Liver glycogen synthesis
over the period of hyperglycemia was increased about
3.5 times in transgenic mice compared to wild-type
[82]. The level of immunodetectable GCK was lower
in the pancreatic islets of transgenic mice with addi-
tional GCK gene copies than in wild-type animals,
perhaps owing to destabilization of the GCK protein
in islets at low glycemic levels.
Another mouse model with overexpression of liver
GCK was produced by transgenesis of GCK cDNA
fused to the phosphoenolpyruvate carboxykinase
(PEPCK) promoter. This construct allowed for high
GCK activity to be maintained in the livers of trans-
genic mice made insulino-deficient by streptozotocin
treatment, while virtual suppression of hepatic GCK
was noted in nontransgenic littermates [83]. Transgenic
mice were largely protected against streptozotocin-
inducedhyperglycemia. Theymaintainednormal levels
of liver glycogen and lactate, compared to severe
depletion of these metabolites in the livers of non-
transgenic diabetic mice, consistent with a determinant
role of GCK in hepatic glycogen synthesis and glycol-
ysis.
The effects of loss of hepatic GCK function on glucose
homeostasis were investigated using a gene targeting
system allowing for liver-specific inactivation of the
GCK gene [84]. Mice with homozygous GCK gene
deletion in the hepatocytes survived to adult age with
virtually complete absence of GCK enzyme activity in
liver tissue. In the freely fed state, the mice exhibited
modest hyperglycemia with relative hyperinsulinemia
compared to controls, indicative of an insulin resistant
state. Liver glycogen in the freely fed state was
normal, implying that gluconeogenesis (and perhaps
high affinity hexokinases) produced sufficient glu-
cose-6-phosphate in the basal state to ensure glycogen
formation and compensate for the ablation of GCK.
However, during a hyperglycemic clamp, the rate of
liver glycogen synthesis failed to rise and whole body
glucose turnover was lower than in control animals.
Interestingly, glucose-induced insulin secretion during
hyperglycemia was markedly diminished in liver
knockout mice, possibly reflecting functional damage
to the b-cells of the islets of Langerhans due to chronic
hyperglycemia and secretory overstimulation [84].
The role of liver GCK in restraining hepatic glucose
output in response to hyperglycemia was also high-
lighted in mice with global heterozygous inactivation
of the GCK gene [85]. These mice exhibited a 50%
reduction of GCK activity in the livers, and presum-
ably in islets and other neuroendocrine cells as well.
Glucose metabolism was investigated by the glucose
clamp technique combined with pancreatic clamping
with somatostatin, in order to maintain circulating
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insulin concentrations at the same fixed level in
knockout and wild-type mice. Hyperglycemia caused
a 10% reduction of the rate of hepatic glucose
production in knockout mice, compared to 40% in
controls, demonstrating that liver GCK is instrumen-
tal in insulin-independent inhibition of hepatic glu-
cose production in response to high glucose [85]. Since
GCK gene inactivation was ubiquitous in these mice,
it cannot be excluded that decreased GCK activity at
extrahepatic sites, for example in the hypothalamus
(see below), might have compromised a neurally-
mediated mechanism contributing to the suppression
of hepatic glucose production during hyperglycemia.
Metabolic role of islet b-cell glucokinase
Regulatory role of glucokinase in the b-cell. Insulin
secretion elicited by hyperglycemia requires stimula-
tion of glucose metabolism in the b-cells. Coupling
between metabolism and secretion relies on the
generation of metabolic products, most prominently
ATP generated by glycolysis and glucose oxidation,
which act as upstream signals in cascades leading to
the stimulation of the exocytic machinery [86, 87]. For
instance, a rise in the cellular ATP/AMP ratio causes
the inhibition of ATP-sensitive K+ channels in the
plasma membrane, leading to membrane depolariza-
tion and activation of voltage-sensitive Ca++ channels.
The influx of extracellular Ca++ ions then somehow
promotes the exocytosis of insulin secretory granules.
The ability of the b-cells to increase their rate of
glucose metabolism in response to a rise in the
extracellular glucose concentration is basic to the
regulation of insulin secretion. The biochemical
properties which allow glucose to regulate its own
metabolism, and thereby insulin secretion, are the
same in the b-cells and in hepatocytes. The first
property is unrestricted glucose transport to ensure
rapid glucose equilibration across the plasma mem-
brane [88, 89]. The second aspect is that glucose
phosphorylation is predominantly catalyzed by GCK
[90], which provides for concentration-dependent
adjustment of the rate of the initial reaction of glucose
metabolism. The third property is a metabolic organ-
ization in which flux along the entire pathways of
glycolysis and glucose oxidation is mostly controlled
at the initial reaction, that catalyzed by GCK.
The extent to which glucose phosphorylation does
control the rate of glycolysis in insulin secreting cells
was investigated in INS-1 derived insulinoma cells
that had been engineered for doxycycline inducible
GCK expression. Moderate increases in GCK activity
elicited by small doses of doxycycline were accom-
panied by quantitatively comparable fractional in-
creases in glycolytic rate at physiologically relevant
extracellular glucose concentration. The fact that the
ratio of fractional increase in glycolytic flux on
fractional increase in GCK activity was close to
unity showed that GCK exerted overwhelming con-
trol over the glycolytic rate [91]. Not surprisingly, at
very high levels ofGCKoverexpression and especially
at high glucose levels, a limit to the increase in
glycolytic flux was attained, indicating that one or
several steps in the lower part of the glycolytic
pathway became limiting [91, 92]. The glyceralde-
hyde-phosphate dehydrogenase reaction was incrimi-
nated as such a step, due to NAD+ depletion [93].
Regulatory role of b-cell glucokinase at the organ-
ismal level. A strategy targeting the neuroendocrine
promoter region of the GCK gene was used to
generate mice with GCK deficiency in the b-cells of
the islets of Langerhans (and other cell-types utilizing
the same promoter) [94]. Mice homozygous for the
deleted allele developed severe diabetes and died
during the first week after birth. Glucose-stimulated
insulin secretion was completely absent in islets from
newborn null mice. Mice heterozygous for the deleted
allele survived to adulthood with slight hyperglyce-
mia, intolerance to a glucose load and reduced
glucose-stimulated hyperinsulinemia. As expected,
GCK activity in islets was reduced to about 50% of
the wild-type level in the heterozygotes. Isolated islets
form heterozygous mice exhibited impaired glucose
stimulated insulin release, most apparent at a glucose
concentration around 10 mM [94]. Similar findings
were reported in mice made deficient in islet GCK
activity by a LoxP strategy using Cre recombinase
expressed from the rat insulin II gene promoter. The
mice with heterozygous inactivation of b-cell GCK
were markedly impaired in ability to raise plasma
insulin during a hyperglycemic clamp in comparison
to controls [84]. Collectively, these data underlined
the role of islet GCK in glucose-induced insulin
secretion and maintenance of glucose homeostasis in
the whole animal. Whether the ablation of GCK in
other neuroendocrine or insulin expressing cellsmight
have contributed to the observed phenotype in the
above experiments remains to be determined.
Glucokinase in the brain
Transgenic mice harboring a chimeric human growth
hormone (hGH) structural gene transcribed from the
rat neuroendocrine GCK promoter had abundant
hGH in their pancreatic islets as expected, and more
surprisingly, also displayed strong immunoreactivity
to hGH in isolated hypothalamic cells [42]. Following
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this discovery, Jetton and colleagues detected GCK
mRNA by reverse transcription-polymerase chain
reaction (RT-PCR) in several regions of the rat brain
and localized GCK transcripts as well as immunor-
eactive protein in situ in the hypothalamus [42].
Subsequently, the neuroendocrine form of GCK
mRNA was selectively identified by RT-PCR assay
as well as in situ hybridization in the ventromedial and
arcuate nuclei of the rat hypothalamus [95]. At the
protein level, immunoblotting and enzyme assays
confirmed the presence of GCK in rat hypothalamic
extracts [96].
In the ventromedial hypothalamus, GCK mRNAwas
shown to be expressed in neurons synthesizing pre-
proopiomelanocortin (POMC) and neuropeptide Y
(NPY)/agouti-related peptide (AgRP), which play
critical roles in neural pathways involved in the
regulation of food intake and energy expenditure.
Experiments using primary cultures of rat hypothala-
mic neurons incubated with metabolic inhibitors such
as mannoheptulose or alloxan suggested that GCK
activity was instrumental for the glucose response of
glucose-excited and glucose-inhibited neurons as well
[97]. Transcript profiling at the single cell level
confirmed the presence of GCK mRNA in approx-
imately 50% of glucose-excited and glucose-inhibited
neurons in the ventromedial area of the hypothal-
amus. Some of these neurons also contained mRNAs
for subunits of ATP-sensitive K+ channels [98]. In
primary cultures of neurons from the rat ventromedial
hypothalamus, treatment with specific small interfer-
ing RNA (siRNA) to knock-down GCK resulted in
the virtual disappearance of excitatory as well as
inhibitory responses to glucose elevation [99]. Col-
lectively, these findings supported the idea that the
glucose sensor of at least a fraction of ventromedial
hypothalamic neurons was GCK, functioning as the
rate determining enzyme of glucose metabolism and
controlling neuronal excitability. However, this pro-
posal raises puzzling questions. First, the interstitial
glucose concentration in brain in the postabsorptive
state is around 1.5 mM, well below the optimal range
of concentrations where GCK displays ultrasensitive
kinetics with respect to glucose concentration. The
second key issue is that of coupling between glucose
metabolism and neuronal activity. Many neurons are
equipped with ATP-sensitive K+ channels, and the
excitability of such neurons might then be controlled
by the rate of glucose metabolism and the attending
fluctuations in cellular ATP content, in ways reminis-
cent of the islet b-cells [100]. Other glucose-derived
metabolites with a signaling role might be intermedi-
ates of the lipogenic pathway [101].
Molecular medicine of glucokinase
Maturity onset diabetes of the young (MODY2).
Approximately 200 mutations of the human GCK
gene, including missense, non-sense, and splice site
mutations, were described in the literature. The
majority of these mutations cause a form of familial
hyperglycemia or mild diabetes, transmitted as an
autosomal dominant trait and often diagnosed before
25 years of age. Based on these characteristics,
diabetes associatedwithGCKmutations was included
in the group of maturity onset diabetes of the young
(MODY), and was named MODY2. Clinically,
MODY2 was defined as a syndrome of impaired
fasting glucose level or mild diabetes, with hyper-
glycemia maintained at stable level for many years,
little propensity for late neurovascular complications
and often adequate glycemic control with diet alone
[102, 103]. Several cases ofMODY2were diagnosed in
women with a history of gestational diabetes [104].
Recently, a new nomenclature was proposed for the
MODY syndromes, MODY2 being replaced by the
descriptive name “familial mild fasting hyperglyce-
mia” [105]. Rare cases of infants inheriting GCK
mutations from two heterozygous parents were de-
scribed in the literature. They presented an autosomal
recessive form of permanent neonatal diabetes melli-
tus (PNDM) [106].
Clinical investigations in patients with MODY2 re-
vealed disorders of liver metabolism and pancreatic
islet function predicted from basic studies in cells and
animals. Net synthesis of glycogen in the liver after
each of three dailymeals was decreased by about 50%
in patients compared to controls [107]. Additionally,
the suppression of hepatic glucose output by hyper-
glycemia was deficient in patients with a GCK
mutation [108]. Patients with a variety of missense
or nonsense GCK mutations exhibited postprandial
plasma insulin levels comparable to controls, although
glucose concentrations were higher in the patients, a
finding compatible with a loss of sensitivity of the b-
cells to glucose. More specifically, during a ramping
glucose infusion, the glucose dose-response curve for
insulin secretion was found to be shifted to the right in
the MODY2 patients [109].
The biochemical properties of many GCK mutants
identified in MODY2 individuals were investigated
using bacterially produced protein. A wide range of
abnormalities affecting the turn-over number of the
enzyme, affinity for the substrates, and cooperativity
with respect to glucose were described [110–112].
Mathematical models based on the kinetics properties
were used to predict the threshold of glucose-stimu-
lated insulin secretion by b-cells harboring a given
heterozygous mutation. On average, prediction for a
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number of mutants was in agreement with the level of
fasting hyperglycemia noted in cohorts of MODY2
patients [111]. Some mutants were found to have
unaltered kinetic properties compared to the wild-
type enzyme, but to display accelerated temperature-
dependent loss of activity in the test tube, in one case
correlating with decreased protein half-life in trans-
duced cells [111, 113].
Several mouse lines with heritable hyperglycemia
were produced through phenotype-driven mutagene-
sis programs using the potent mutagen N-ethyl-N-
nitrosourea (ENU). Interestingly, the majority of
hyperglycemic lines that were genetically character-
ized so far harbored mutations in the GCK gene [114,
115], several of which corresponded to mutations that
had been described in pedigrees with MODY2 or in
one case in PNDM [116]. These mice displayed
spontaneous hyperglycemia in the freely fed state,
and glucose intolerance accompanied by relative
hypoinsulinemia after an oral glucose load, similar
to abnormalities found in human MODY2 patients
[116].
Persistent hyperinsulinemic hypoglycemia of infancy
(PHHI). A small number of heterozygous missense
GCK mutations were identified as probable cause of
hyperinsulinism in infancy, a rare syndrome charac-
terized by chronic low fasting plasma glucose and
bouts of symptomatic hypoglycemia [117]. Kinetic
studies of the mutant enzymes revealed an increase in
glucose affinity with or without increased turnover
number (kcat) [118–120]. A gene knock-in strategy
was used to produce mice with a GCK allele encoding
a hyperactive mutant GCK with increased affinity for
glucose. The mice were hyperinsulinemic relative to
their plasma glucose levels. However, the severity of
hypoglycemia was less than expected, suggesting a
compensatory mechanism in the liver. Paradoxically,
liver GCK activity and protein content in these mice
were lower than normal, suggesting the possibility of a
shorter half-life of themutant enzyme due to impaired
interaction with GCKR [121].
Small-molecule activators of glucokinase as potential
antidiabetic drugs
Type 2 diabetes melltus (T2D) is a common disease of
multifactorial etiology, in which both a genetic pre-
disposition determinedbymultiple genes, and lifestyle
factors such as excess calorie intake and low physical
activity, play causative roles. The increasing preva-
lence of T2D, and its serious consequences on health
at both the individual and public levels, create
incentives for the development of novel antidiabetic
drugs. Physiopathologically, T2D consists of defective
insulin action in target tissue, including reduced
insulin suppression of liver glucose production, and
defective insulin secretion and other functions in the
b-cells of the islets of Langerhans [122]. The central
role ofGCK in facilitating glucose disposal by the liver
on the one hand, and insulin secretion by the islets of
Langerhans on the other hand, provided a strong
rationale for the search of small molecule activators of
GCK in drug discovery programs aimed at developing
a new class of antidiabetic drugs. Such programs were
implemented by several major drug companies, and a
limited number ofmolecules acting asGCKactivators
are currently in early stages of clinical trials.
Small molecule activators of GCK emerged from a
high throughput screening strategy based on the
capacity of chemicals to increase the activity of
recombinant GCK in an enzyme assay mixture con-
taining GCKR. The first promising compound was
described in 2003 by Grippo and colleagues [123] and
shown actually to be a direct activator of GCK in the
absence of GCKR. This compound, designated RO-
28-1675, had the dual effects of increasing both the
affinity for glucose and the turnover number of GCK,
that is, it shifted the glucose S0.5 of GCK from 8.5 mM
to 0.8 mM and increased the kcat by approximately
80% at maximal concentration. When added to
isolated rat islets of Langerhans, RO-28-1675 stimu-
lated the rate of glycolysis, lowered the threshold for
glucose-stimulated insulin secretion and increased the
maximal secretory response. A single oral adminis-
tration of RO-28-1675 to normal or obese mice had a
clear-cut hypoglycemic effect accompanied by hyper-
insulinemia. Treatedmice displayed improved glucose
tolerance after an oral glucose load. Endogenous
glucose production was reduced during a hyperglyce-
mic hyperinsulinemic clamp in RO-28-1675-treated
rats compared to controls, consistent with an effect of
the drug on hepatic GCK activity [123]. A variety of
chemically distinct small molecule activators of GCK
were subsequently discovered in several laboratories.
The biochemical and cellular effects, as well as
biological actions in experimental animals, were
essentially similar to those of the prototype RO-28-
1675 [19, 124–126]. An expert review of the current
status of GCK activators in drug development was
recently published [127].
An implicit hope in developing activators of the
physiological glucose sensor was the idea of restoring
“physiological” glucose-sensing, particularly in the
islet b-cells. However, the strong increase in the
glucose affinity of GCK induced by all activators
known to date might drastically lower the threshold
for insulin release and causemaximal insulin secretion
at low plasma glucose levels. Whether the design of
Cell.Mol. Life Sci. Vol. 66, 2009 Review Article 37
drug preparations without liability of inducing serious
hypoglycemia is possible remains to be seen. Another
concern with GCK activators is related to the activa-
tion of hepatic lipogenesis leading to hepatosteatosis
(and associated insulin resistance), as was noted in
transgenic mice with hepatic overexpression of GCK
[128, 129]. Finally, in a more general vein, the long
term benefit of using insulinotropic agents in the
treatment of T2D (at least early in the disease) was
recently questioned, because of concerns about the
possibility of precipitating islet failure through hyper-
secretory activity [130].
Conclusions and perspectives
The evidence presented in this review should leave
little doubt about the status of GCK as an eminent
player in the regulation of glucose metabolism and
homeostasis. This status relies on the mechanism
whereby GCK operates as an ultrasensitive glucose
sensor, recently illuminated by structural data. The
localization of such a sensor inside, rather than on the
surface, of cells is striking. It is increasingly clear that
the traffic of GCK between distinct subcellular sites,
regulated by reversible interactions with diverse
scaffold proteins, might contribute to shape the
metabolic activity of cells, but by which exact molec-
ular mechanisms remains to be explained, notably in
the pancreatic b-cells. In hypothalamic nuclei and
other brain areas, it will be important to resolve the
apparent paradox of GCK operating under less than
optimal glucose concentrations for substrate regula-
tion of the enzyme reaction. Some of the most
intriguing unanswered questions pertain to the regu-
lation of GCK gene expression in hepatocytes. The
transcriptional induction of GCK is a dramatic effect
of insulin in the liver, perhaps the best example of
induction of any gene in any cell-type by insulin.
However, details about the regulatory proteins of
transcription which mediate this effect are still a black
box. The burstlike pattern of regulation of GCK
transcription in rat liver with very large, rapid and
transient inductive effects of insulin for a protein with
relatively slow turnover raises puzzling questions with
respect to the biological advantage that might arise
from this type of regulation. In the diabetes field, the
development of GCK activators through the preclin-
ical phase has generated exciting results, but also
illustrated some liabilities. If these can be overcome,
drugs with a novel mechanism of action will become
available as an additional option in the panoply of oral
antidiabetics.
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